Pam Bounelis Selected Research

Azaserine

4/2004	Hexosamine pathway is responsible for inhibition by diabetes of phenylephrine-induced inotropy.
12/2002	Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pam Bounelis Research Topics

Disease

3	Hyperglycemia 06/2006 - 12/2002
1	Wounds and Injuries (Trauma) 06/2006
1	Shock 06/2006
1	Hemorrhage 06/2006
1	Ischemia 02/2006
1	Hypertrophy 12/2002

Drug/Important Bio-Agent (IBA)

4	HexosaminesIBA 06/2006 - 12/2002
3	Proteins (Proteins, Gene)FDA Link 06/2006 - 12/2002
3	Glucosamine (Dona)IBA 06/2006 - 04/2004
2	CalciumIBA 02/2006 - 12/2002
2	AzaserineIBA 04/2004 - 12/2002
1	AcetylglucosamineIBA 06/2006
1	Inositol (Myoinositol)IBA 04/2004
1	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 04/2004
1	Type C PhospholipasesIBA 04/2004
1	Angiotensin IIIBA 12/2002
1	Transcription Factors (Transcription Factor)IBA 12/2002
1	Adenosine Triphosphatases (ATPase)IBA 12/2002
1	ThapsigarginIBA 12/2002
1	Nuclear Localization Signals (Nuclear Localization Signal)IBA 12/2002

Therapy/Procedure

1	Resuscitation 06/2006